- Foliar application of CELEXT07 bio-defense stimulant extract
alone or in combination with a botanically-derived antimicrobial
plant extract results in the prevention and suppression of powdery
mildew on cannabis leaves.
- CELEXT07 is a strong alternative to synthetic fungicides for
cannabis growers in search of eco-friendly alternatives.
- CELEXT07 extract is ready to market: production capacity
secured to meet demand from potential clients.
MONTREAL, March 18, 2019 /CNW/ – Mondias Naturals
Inc. ("Mondias" or the "Company") (TSXV: NHP) is pleased to
announce the results of its greenhouse production tests conducted
in collaboration with McGill University
and a leading cannabis producer on its proprietary CELEXT07
bio-defense stimulant plant extract.
Mondias has been developing CELEXT07 to help prevent fungal
growth on plants through its proven ability to boost plant defense
systems. The objective of the tests was to measure the product's
efficacy in reducing and suppressing the most common fungal
diseases encountered in cannabis through the application of
CELEXT07 alone and in combination with a botanically-derived
antimicrobial plant extract grown in greenhouse production
systems.
Summary of the test results:
- Preliminary results showed that foliar application of CELEXT07
alone resulted in the prevention of powdery mildew on cannabis
leaves.
- Foliar application of CELEXT07 combined with the tested
botanically-derived antimicrobial plant extract resulted in the
prevention and suppression of powdery mildew on the leaves of three
commercial varieties of cannabis. This combination was the most
effective in protecting the cannabis variety most susceptible to
powdery mildew.
- When applied alone or in combination with the tested
botanically-derived antimicrobial plant extract as a foliar spray,
CELEXT07 did not produce any phytotoxic effects on cannabis
leaves.
- Soil drench application of CELEXT07 helped suppress grey mould
on hops, a close relative of cannabis.
"These results validate the effectiveness of CELEXT07's
bio-defense stimulant properties and open up a large potential
market for Mondias, especially as the testing was done in
collaboration with a leading cannabis producer," said Jean-Philippe Gravel, Chief Executive Officer of
Mondias. "Furthermore, cannabis growers are seeking eco-friendly
alternatives to pesticides. The results from these greenhouse
production tests will allow us to market CELEXT07 to a growing
number of Canadian cannabis producers. The product is ready to
market, and we have secured the production capacity we need to meet
demand from potential clients."
With post-harvest losses of one-third of the food produced
worldwide for human consumption (Gastavsson et al., 2011) and
annual economic losses of $10 billion
to $100 billion worldwide due to grey
mould and powdery mildew (L. Hua et al., 2018), the market
potential for CELEXT07 is considerable.
About Mondias Natural Products Inc.
Mondias specializes in the commercialization and development of
evidence-based botanical products for the health care,
bio-agriculture and organic markets. The company sells both oral
and topical botanical agents to help manage unmet medical needs
through its Holizen Laboratories division. Mondias is also
developing botanical-based specialty fertilizers for use on
household plants, lawns and golf courses and in urban gardens,
nurseries and greenhouses, in collaboration with McGill's Faculty of Agricultural and Environmental
Sciences.
For more information, visit: mondias.ca
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking
information. All statements, other than of historical fact, that
address activities, events or developments that the Company
believes, expects or anticipates will or may occur in the future
(including, without limitation, statements regarding potential
acquisitions and financings) are forward-looking statements.
Forward-looking statements are generally identifiable by use of the
words "may", "will", "should", "continue", "expect", "anticipate",
"estimate", "believe", "intend", "plan" or "project" or the
negative of these words or other variations on these words or
comparable terminology. Forward-looking statements are subject to a
number of risks and uncertainties, many of which are beyond the
Company's ability to control or predict, that may cause the actual
results of the Company to differ materially from those discussed in
the forward-looking statements. Factors that could cause actual
results or events to differ materially from current expectations
include, among other things, without limitation, the inability of
the Company to obtain sufficient financing to execute the Company's
business plan; competition; regulation and anticipated and
unanticipated costs and delays, the success of the Company's
research and development strategies, the success of this joint
venture, the ability to obtain orphan drug status, the
applicability of the discoveries made therein, the successful and
timely completion and uncertainties related to the regulatory
process, the timing of clinical trials, the timing and outcomes of
regulatory or intellectual property decisions and other risks
disclosed in the Company's public disclosure record on file with
the relevant securities regulatory authorities. Although the
Company has attempted to identify important factors that could
cause actual results or events to differ materially from those
described in forward-looking statements, there may be other factors
that cause results or events not to be as anticipated, estimated or
intended. Readers should not place undue reliance on
forward-looking statements. While no definitive documentation has
yet been signed by the parties and there is no certainty that such
documentation will be signed. The forward-looking statements
included in this news release are made as of the date of this news
release and the Company does not undertake an obligation to
publicly update such forward-looking statements to reflect new
information, subsequent events or otherwise unless required by
applicable securities legislation.
SOURCE Mondias Natural Products Inc.